I

105TH CONGRESS

1ST SESSION H. R. 953

To amend the Public Health Service Act to provide for programs regarding

ovarian cancer.

IN THE HOUSE OF REPRESENTATIVES

MARCH 5, 1997

Mrs. MINK of Hawaii (for herself, Mr. ACKERMAN, Ms. CHRISTIAN-GREEN,

Ms. DEGETTE, Mr. EVANS, Mr. FROST, Ms. EDDIE BERNICE JOHNSON

of Texas, Ms. LOFGREN, Ms. MCKINNEY, Mrs. MALONEY of New York,

Mr. MASCARA, Mrs. MEEK of Florida, Mrs. MORELLA, Ms. SANCHEZ,

Ms. SLAUGHTER, and Ms. WOOLSEY) introduced the following bill; which

was referred to the Committee on Commerce

A BILL

To amend the Public Health Service Act to provide for

programs regarding ovarian cancer.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the ‘‘Ovarian Cancer

5 Research and Information Amendments of 1997’’.

6 SEC. 2. FUNDING FOR RESEARCH ON OVARIAN CANCER.

7 Section 417B(b)(2) of the Public Health Service Act

8 is amended—
2

HR 953 IH

1 (1) by striking ‘‘CANCERS.—For the purpose

2 of’’ and all that follows through ‘‘417,’’ and insert3 ing the following: ‘‘CANCERS.—

4 ‘‘(A) For the purpose of carrying out sec5 tion 417(d),’’; and

6 (2) by adding at the end the following subpara7 graph:

8 ‘‘(B)(i) For the purpose of carrying out re9 search under section 417(d) on ovarian cancer,

10 there are authorized to be appropriated

11 $90,000,000 for fiscal year 1998, and such

12 sums as may be necessary for each of the fiscal

13 years 1999 and 2000. With respect to such pur14 pose, such authorizations of appropriations are

15 in addition to the authorizations of appropria16 tions established in subparagraph (A) and in

17 subsection (a).

18 ‘‘(ii) Of the amounts appropriated under

19 clause (i) for a fiscal year, the Director of the

20 Institute shall reserve 50 percent for research

21 described in such clause that does not involve

22 treatment or clinical trials, and 50 percent for

23 research described in such clause that does in24 volve treatment and clinical trials.
3

HR 953 IH

1 ‘‘(iii) In expending the amounts reserved

2 under clause (ii) for a fiscal year, the Director

3 of the Institute shall ensure that 1 or more pro4 grams of research on ovarian cancer are carried

5 out under the programs designated by the Di6 rector as the Specialized Programs of Research

7 Excellence.’’.

8 SEC. 3. PUBLIC INFORMATION AND EDUCATION ON OVAR9 IAN CANCER.

10 Section 417(d)(4) of the Public Health Service Act

11 is amended by striking ‘‘section 413; and’’ and inserting

12 the following: ‘‘section 413, which programs shall include

13 programs on ovarian cancer that (subject to changes in

14 the applicable facts) provide information and education re15 garding—

16 ‘‘(A) screening procedures for such cancer,

17 including the fact that there is not a procedure

18 that reliably provides for the early detection of

19 such cancer;

20 ‘‘(B) the fact that there may be a genetic

21 basis to such cancer;

22 ‘‘(C) factors indicating a substantial risk

23 of such cancer; and
4

HR 953 IH

1 ‘‘(D) the various treatments for such can2 cer and the extent to which the treatments are

3 effective; and’’.

4 SEC. 4. EFFECTIVE DATE.

5 This Act takes effect October 1, 1997, or upon the

6 date of the enactment of this Act, whichever occurs later.

Æ